Bank of New York Mellon Corp Has $2.90 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Bank of New York Mellon Corp lifted its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 3.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,181 shares of the biotechnology company’s stock after purchasing an additional 3,578 shares during the quarter. Bank of New York Mellon Corp owned about 0.44% of Arcturus Therapeutics worth $2,902,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Sumitomo Mitsui Trust Holdings Inc. increased its stake in Arcturus Therapeutics by 22.4% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock valued at $38,061,000 after buying an additional 286,546 shares during the last quarter. Great Lakes Advisors LLC bought a new position in Arcturus Therapeutics in the 4th quarter valued at $6,531,000. Dimensional Fund Advisors LP boosted its holdings in Arcturus Therapeutics by 11.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,088,930 shares of the biotechnology company’s stock valued at $34,336,000 after purchasing an additional 115,087 shares during the period. Nordea Investment Management AB bought a new stake in shares of Arcturus Therapeutics during the 1st quarter worth $1,846,000. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Arcturus Therapeutics during the 1st quarter worth $1,865,000. Institutional investors own 94.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. HC Wainwright boosted their price objective on shares of Arcturus Therapeutics from $60.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Leerink Partnrs raised shares of Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. William Blair reiterated an “outperform” rating on shares of Arcturus Therapeutics in a research note on Thursday, May 23rd. Leerink Partners began coverage on shares of Arcturus Therapeutics in a research report on Monday, August 12th. They set an “outperform” rating and a $70.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $71.40.

Arcturus Therapeutics Stock Up 4.2 %

NASDAQ ARCT opened at $20.75 on Monday. The firm has a market cap of $558.80 million, a PE ratio of -5.31 and a beta of 2.60. The company has a 50 day moving average price of $21.33 and a 200 day moving average price of $27.68. Arcturus Therapeutics Holdings Inc. has a 52 week low of $17.52 and a 52 week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The business had revenue of $49.86 million for the quarter, compared to the consensus estimate of $21.00 million. During the same period in the prior year, the firm earned ($1.98) EPS. On average, equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.6 earnings per share for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.